US Patent 11365241 High concentration anti-C5 antibody formulations
Patent 11365241 was granted and assigned to Alexion Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 19 Jun, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Apr, 2023
Golden AI
Edits on 7 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113652410
Date of Patent
June 21, 2022
0Patent Application Number
166339300
Date Filed
July 27, 2018
0Patent Citations
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113652410
Date of Patent
June 21, 2022
0Patent Application Number
166339300
Date Filed
July 27, 2018
0Patent Citations
Patent Primary Examiner
Edits on 22 Jun, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+548 characters)
US Patent 11365241 High concentration anti-C5 antibody formulations
Article
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), using the solutions. Also featured were therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11365241
Date of patent
June 21, 2022
Patent application number
16633930
Date Filed
July 27, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 11365241 High concentration anti-C5 antibody formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
